NCT07672899 Small RNA tRF-31 Changes in Patients With Age-Related Cataract
| NCT ID | NCT07672899 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Cataract |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-06-17 |
| Primary Completion | 2026-08-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-06-17 with a primary completion date of 2026-08-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to evaluate the expression characteristics and clinical relevance of the tRF-31/HIPK2 signaling axis in adults over 18 years old with age-related cataract (ARC). The main questions it aims to answer are: Is there a correlation between the relative expression levels of tRF-31 and its target gene HIPK2 in the anterior lens capsule and the clinical severity (Emery-Little grading system) of age-related cataracts? Does oxidative stress in the anterior segment microenvironment have a potential bystander effect on the state of the corneal endothelium? Participants will:Undergo routine preoperative ophthalmologic examinations, including visual acuity tests, slit-lamp photography, and corneal endothelial cell counting. Undergo standard cataract surgery (phacoemulsification combined with intraocular lens implantation) as part of their regular medical care. Allow researchers to collect and analyze their anterior lens capsule tissue, which is routinely removed and typically discarded as medical waste during the standard continuous curvilinear capsulorhexis (CCC) step of the surgery.
Eligibility Criteria
Inclusion Criteria: Patients older than 18 years. Clinically diagnosed with age-related cataract (ARC) and have clear surgical indications for routine phacoemulsification combined with intraocular lens (IOL) implantation. Scheduled to undergo cataract extraction and intraocular lens implantation. Completed routine preoperative corneal endothelial specular microscopy, providing objective data including cell density, coefficient of variation of cell area, and the proportion of hexagonal cells. Provided signed written informed consent. Exclusion Criteria: History of ocular trauma, glaucoma, episodes of active uveitis, or previous intraocular surgery. Presence of severe systemic diseases rendering the patient unsuitable for surgery. Poor patient compliance or coexisting psychiatric disorders. Severe systemic metabolic syndromes (e.g., diabetes). Diagnosis of high myopia. Current participation in other clinical trials or likelihood of being lost to follow-up.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07672899 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cataract. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07672899 currently recruiting?
Yes, NCT07672899 is actively recruiting participants. Contact the research team at yyzbzhong@zju.edu.cn for enrollment information.
Where is the NCT07672899 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07672899 clinical trial?
NCT07672899 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The trial plans to enroll 200 participants.